您当前所在的位置:首页 > 产品中心 > 产品信息
Doxorubicin hydrochloride_分子结构_CAS_25316-40-9)
点击图片或这里关闭

Doxorubicin hydrochloride

产品号 Bio-0029 公司名称 InterBioScreen
CAS号 25316-40-9 公司网站 http://www.ibscreen.com
分子式 C27H30ClNO11 电 话 +7 49652 40091
分子量 579.9802 传 真 +7 49652 40092
纯 度 电子邮件 screen@ibscreen.chg.ru
保 存 Chembase数据库ID: 72574

产品价格信息

请登录

产品别名

标题
Doxorubicin hydrochloride
IUPAC标准名
(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione hydrochloride
IUPAC传统名
(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione hydrochloride
别名
Adriamycin

产品登记号

CAS号 25316-40-9

产品性质

应用领域 Antineoplastic antibiotic
应用领域 Shows anti-HIV activity
应用领域 Possesses an antitumor effect against a wide spectrum of tumors
应用领域 Used in the treatment of ovarian cancer and AIDS related Kaposi sarcoma
生物来源 Metab. of Streptomyces peucetius
成盐信息 HCl
生物活性机理 Forms complexes with DNA by intercalation between base pairs
生物活性机理 Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes
生物活性机理 May also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA

产品详细信息

参考文献

  • Arcamone, F. et al., Tet. Lett., 1969, 1007, (struct, ir, uv, ms, nmr)
  • IARC Monog., 1976, 10, 43; Suppl. 6, 35; Suppl. 7, 82, (rev, tox)
  • Smith, T.H. et al., J.A.C.S., 1976, 98, 1969, (synth)
  • Arnone, A. et al., Tet. Lett., 1976, 3349, (cmr)
  • Suzuki, F. et al., J.A.C.S., 1978, 100, 2272, (synth)
  • Swenton, J.S. et al., J.A.C.S., 1978, 100, 6188, (synth, ir, uv, ms, nmr)
  • Vigevani, A. et al., Anal. Profiles Drug Subst., 1980, 9, 245, (rev, synth, anal)
  • Cassinelli, G. et al., J. Antibiot., 1980, 33, 1468; 1982, 35, 176, (derivs)
  • Cassinelli, G. et al., J.A.C.S., 1980, 102, 1462, (derivs)
  • Gioia, B. et al., Biomed. Mass Spectrom., 1984, 11, 35, (ms, derivs)
  • White, R.J. et al., Drugs Pharm. Sci., 1984, 22, 569, (rev)
  • Barranco, S.C., Pharmacol. Ther., 1984, 24, 303, (rev, pharmacol)
  • Brown, J.R. et al., Prog. Med. Chem., 1984, 21, 169, (rev)
  • Traganos, F. et al., Cancer Res., 1985, 45, 6273-6279; 1991, 51, 3682-3689, (AD 198)
  • Acton, E.M., Drugs Exp. Clin. Res., 1985, 11, 1, (A 489, rev)
  • Acton, E.M. et al., J. Med. Chem., 1986, 29, 1225, (A 489, synth)
  • U.S. Pat., 1986, Univ. of Tennessee, 4 610 977; CA, 105, 209343v, (AD 198)
  • Allman, T. et al., Can. J. Chem., 1987, 65, 2405, (pmr, conformn)
  • Kajii, K. et al., Iyakuhin Kenkyu, 1987, 18, 704, (Pirarubicin, uv, ir, pmr, struct)
  • Nakashima, H., J. Antibiot., 1987, 396, (anti-HIV activity)
  • Negwer, M., Organic-Chemical Drugs and their Synonyms, 6th edn., Akademie-Verlag, 1987, 7522
  • Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 475; 477; 497
  • Barthwal, R. et al., J. Mol. Struct., 1994, 327, 201, (pmr, conformn)
  • Harstrick, A. et al., Anti-Cancer Drugs, 1995, 6, 681-685, (AD 198)
  • Coukell, A.J. et al., Drugs, 1997, 53, 453-482; 520-538, (Epirubicin, Doxorubicin, pharmacol, rev)
  • Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, AES750; EBB100; HKA300; COP765; DAM800